Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials
-
Published:2020
Issue:5
Volume:9
Page:596-612
-
ISSN:2235-1795
-
Container-title:Liver Cancer
-
language:en
-
Short-container-title:Liver Cancer
Author:
Koroki Keisuke, Ogasawara SadahisaORCID, Ooka Yoshihiko, Kanzaki Hiroaki, Kanayama Kengo, Maruta Susumu, Maeda Takahiro, Yokoyama Masayuki, Wakamatsu Toru, Inoue Masanori, Kobayashi Kazufumi, Kiyono Soichiro, Nakamura Masato, Kanogawa Naoya, Saito Tomoko, Kondo Takayuki, Suzuki Eiichiro, Nakamoto Shingo, Yasui Shin, Tawada Akinobu, Chiba Tetsuhiro, Arai Makoto, Kanda TatsuoORCID, Maruyama Hitoshi, Kato Jun, Kuboki Satoshi, Ohtsuka Masayuki, Miyazaki Masaru, Yokosuka Osamu, Kato Naoya
Abstract
Background: Intermediate-stage hepatocellular carcinoma (HCC) has a high frequency of recurrence and progression to advanced stage after transarterial chemoembolization (TACE), particularly in patients with high tumor burden. Promising new results from immune checkpoint inhibitors (ICIs) and ICI-based therapies are expected to replace TACE, especially in HCC patients with high tumor burden. Aims: The present study aimed to evaluate the effectiveness of TACE with a view to design clinical trials comparing TACE and ICIs. Methods: We retrospectively identified intermediate-stage HCC patients undergoing TACE from our database and subdivided patients into low- and high-burden groups based on three subclassification models using the diameter of the maximum tumor and the number of tumors. Clinical outcomes were compared between low- and high-burden intermediate-stage HCC. Results: Of 1,161 newly diagnosed HCC patients, 316 were diagnosed with intermediate-stage disease and underwent TACE. The median overall survival from high-burden intermediate-stage disease was not significantly different by clinical course, reaching high tumor burden in all subclassification models. The prognosis of high-burden patients after initial TACE was poor compared with low-burden patients for two models (except for the up-to-seven criteria). In all three models, high-burden patients showed a poor durable response rate (DRR) both ≥3 months and ≥6 months and poor prognosis after TACE. Moreover, patients with confirmed durable response ≥3 months and ≥6 months showed better survival outcomes for high-burden intermediate-stage HCC. Conclusions: Our results demonstrate the basis for selecting a population that would not benefit from TACE and setting DRR ≥3 months or ≥6 months as alternative endpoints when designing clinical trials comparing TACE and ICIs.
Subject
Oncology,Hepatology
Reference41 articles.
1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018 Mar;391(10127):1301–14. 2. Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015 Sep;35(9):2155–66. 3. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003 Feb;37(2):429–42. 4. Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al.; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018 Jul;69(1):182–236. 5. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017 Jul;11(4):317–70.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|